Navigation Links
Sangamo BioSciences Announces Presentation Of Clinical Data From Alzheimer's Disease Program
Date:11/15/2013

Disease (AD)
Alzheimer's disease is a progressive disorder of the brain that gradually affects one's memory and ability to learn, reason, communicate and carry out daily activities. There are now more than five million people in the United States living with AD, and there is currently no cure.

About CTAD
Since 2008, CTAD has been a conference organized and planned by AD clinical researchers for AD clinical researchers. CTAD embraces the organizing committee mandate to maintain CTAD's unique role in AD research: To provide a substantive, clinical research-oriented conference and an annual opportunity for the world's preeminent clinical researchers to engage in both formal and informal exchanges of views. CTAD's ongoing commitment to providing a relatively intimate forum has resulted in the conference's reputation of facilitating and fostering international collaboration in AD clinical research matters. More information is available at www.ctad-alzheimer.com.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 and Phase1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. As part of its acquisition of Ceregene Inc., Sangamo acquired a fully-enrolled and funded, double-blind, placebo-controlled Phase 2 trial to evaluate NGF-AAV (CERE-110) in Alzheimer's disease. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and  hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sangamo BioSciences Reports Third Quarter 2013 Financial Results
2. Sangamo BioSciences Announces Closing Of $74.2 Million Public Offering Of Common Stock And Exercise Of Over-Allotment Option
3. Sangamo BioSciences Proposes Public Offering Of Common Stock
4. Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL
5. Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference
6. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
7. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
8. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
9. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
10. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
11. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 19, 2014  Roche (SIX: RO, ROG; OTCQX: ... Inc. (Bina), a privately held company based in ... Bina provides a big data platform for centralized ... data. Bina,s proprietary on-market Genomic Management Solution, Bina-GMS ... to perform fast and scalable analyses to maximize ...
(Date:12/19/2014)... (PRWEB) December 18, 2014 ... nation’s leading specialty pharmacies, has an expanded team ... clinical pharmacy consultants for prescriber offices in their ... , “We have a variety of Regional ... example, those specializing in hepatitis C help prescribers ...
(Date:12/19/2014)... Reports from CDC show approximately 117 ... or more chronic health conditions - including cardiovascular disease, ... of these diseases, but may not eliminate the severe ... implanted nerve stimulation devices today offer relief, they require ... induce side effects. , To eliminate the need ...
(Date:12/19/2014)... San Diego, CA (PRWEB) December 18, 2014 ... announces a limited time special on Sartorius Biohit ... 1 Free on mLINE pipettes, Picus Electronic Pipette Trade-in ... recommended by Health and Safety officers around the world. ... repetitive manual pipetting. Other features include:, , ...
Breaking Biology Technology:Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2
... System Offers Healthcare Workers Consistent Cleaning , ... , IRVINE, Calif., Dec. 16 ... the availability of the EVOTECH(TM) Endoscope Cleaner and ... labor-intensive manual cleaning of endoscopes. The results of ...
... to review Intermezzo(R) (zolpidem tartrate sublingual lozenge) as the ... middle-of-the-night awakenings , , ... a privately-held specialty pharmaceutical company, announced today that it ... Administration (FDA) that the New Drug Application (NDA) for ...
... Dec. 16 Anesiva,Inc. (Nasdaq: ANSV ... Phase 3,trial evaluating Adlea(TM), its long-acting, non-opioid analgesic ... post-surgical,pain versus placebo (p=0.03) following total knee arthroplasty ... 48 hours after surgery. The trial also,met its ...
Cached Biology Technology:ASP Announces Availability of EVOTECH(TM) Endoscope Cleaner and Reprocessor - First Commercially Available System to Eliminate Manual Cleaning of Endoscopes 2Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R) 2Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R) 3Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R) 4Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R) 5Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery 2Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery 3Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery 4
(Date:12/11/2014)... Dec. 10, 2014  That blood pressure plays a role ... Hypertension – the medical term for high blood pressure – ... and the inflatable cuff that,s used in measuring blood pressure ... there,s nothing new about hypertension, its triggers and its effects. ... the condition and the best ways to treat it. ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here ... account but can,t remember your password, site key or the ... was your first grade teacher? Today, ... the app that will finally put an end to ... 1U TM . 1U leverages a user,s smartphone ...
(Date:12/10/2014)... 9, 2014  Wake Forest Baptist Medical Center today announced ... School of Medicine. Funding for this $50 million capital ... will be publicly launched next summer. ... former 60 series R.J. Reynolds Tobacco Company complex, adjacent ... begin immediately with plans to be ready to welcome ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... way to scan brain tumors and predict which ones will ... ever starts treatment. By linking high water movement in ... 70 percent accuracy which patients, tumors were the least likely ... considers himself lucky. When his aggressive brain cancer returned ...
... parts of living organisms come packaged with ribbons. The ... into three-dimensional structures to work properly. But when for ... happen, and in humans misfolded-protein disorders include Alzheimer,s and ... three decades tried to understand what makes proteins fold ...
... trees have declined in Yosemite National Park during the ... role. The number of large-diameter trees in the ... U.S. Geological Survey and University of Washington scientists compared ... to the most recent records from 1988�. A ...
Cached Biology News:A crystal ball for brain cancer? 2A crystal ball for brain cancer? 3New computer simulation helps explain folding in important cellular protein 2New computer simulation helps explain folding in important cellular protein 3
... Clean and Accurate Results Laser Capture ... the sensitivity and accuracy of molecular assays ... types and multi-cellular structures isolated from whole ... to microdissection-developed in 1996 at the National ...
... antibody raised against a partial ... Immunogen: ZFHX4 (NP_078997, 2 ... recombinant protein with GST tag. ... NM_024721 ...
... specificity and signaling of the members of ... modified by alternative splicing--which has important implications ... can perform a classical expression profiling and ... alternatively spliced forms of the gene that ...
... Alternative Splicing plays an important role in ... apoptosis and cell death. Splice variants have ... and inhibition of defined apoptotic pathways. With ... can perform a classical expression profiling and ...
Biology Products: